A HUB OF EXCELLENCE IN LIFE SCIENCES

RESEARCH AREA

INAB|CERTH is at the forefront of research across all domains in Life Sciences

PILLARS

Bioanalysis, Real world evidence, Implementation science

ΜISSION

To address the gap between research excellence in Life Sciences and applications that meet end-user demands

INAB
NEWS

Hosting of “Master Food Identity”

From June 20th to July 1st, the Institute of Applied Biosciences, as main partn…

Participation of the Health Psychology Team in th…

The Health Psychology Team of INAB|CERTH, participated for the second consecuti…

Organization of the Food Identity MS program

Since 2017, ΙΝΑΒ is a partner and co-organizes a Master Program in Food Identit…

Approval of participation in the Network of Rese…

Approval of participation in the Network of Researchers on the Chemical Evoluti…

Exploration of the role of biological data in pre…

The European research project PROTEIN aims to promote a healthy lifestyle, prev…

Placeholder

Organization of educational seminar for the manag…

In the frame of the EpiMilk research project "Development of an integrated syst…

INAB hosts meeting with the European Clinical Res…

INAB hosts the meeting with Jacques Demotes, President of the European Clinical…

Placeholder

Identification of SARS-CoV-2 virus in mink farms …

During the SARS-CoV-2 virus crisis, INAB, in cooperation with the Regions of Ce…

Placeholder

Genetic identification of small ruminant breeds

Since 2018, the scientific team of INEB is responsible for the genetic characte…

INAB
ONE HEALTH

INAB
INSTITUTE OF
APPLIED BIOSCIENCES

The Institute of Applied Biosciences at the Centre for Research and Technology Hellas, INAB|CERTH, conducts research in the Life Sciences that extends from microbes to plants,
animals and humans. Our aim at INAB is to promote basic research, while providing solutions to
important social needs related to health and well-being. In this context, INAB conducts Biomedical research and deals with the development and evaluation of digital health
interventions and personalized medicine, while also holding a leading position in Agri-biotechnology, utilizing modern high-performance methodologies, molecular 
biotechnology and ‘breeding by design’ approaches, with the aim of developing high quality and value products. We work towards this direction with the basic principle of cooperation between scientists with different but complementary knowledge and skills. The main pillars of our
activity are bioanalysis, real world data and the development of relevant applications.

The Institute of Applied Biosciences at the Centre for Research and Technology Hellas, INAB|CERTH, conducts research in the Life Sciences that extends from microbes to plants, animals and humans. Our aim at INAB is to promote basic research, while providing solutions to important social needs related to health and well-being. In this context, INAB conducts Biomedical research and deals with the development and evaluation of digital health interventions and personalized medicine, while also holding a leading position in Agri-biotechnology, utilizing modern high-performance methodologies, molecular biotechnology and ‘breeding by design’ approaches, with the aim of developing high quality and value products. We work towards this direction with the basic principle of cooperation between scientists with different but complementary knowledge and skills. The main pillars of our activity are bioanalysis, real world data and the development of relevant applications.

we rely
on knowledge & cooperation

we innovate
in the Life Sciences

we respond
to social needs

INAB
Certifications

The vision of ΙΝΑΒ is to maintain the highest possible level of quality in the entire spectrum of its operations and services.

INAB has established a robust Integrated Information Security (IS) and Business Continuity (BC) Management System, certified according to ISO/IEC 27001:2013 and ISO 22301:2019 respectively. This system, diligently maintained since 2018, underscores INAB’s commitment to security, data protection and operational resilience.

INΑB has installed and implements a Quality Management System according to the ELOT EN ISO/IEC 15189:2012 Standard, the relevant documents of ESYD, as well as any other specifications related to the activities of the Laboratories. ΙΝΑΒ is committed to complying with the requirements of the above Standard and continuously improving its efficiency. The system is maintained since 2018.

The laboratories participate in external quality control schemes and are constantly updating their certificates as well as enriching their fields of accreditation with new ones. You can see here, the Institute’s “Table of Participation in external quality assessment schemes”.

PARTICIPATION IN EXTERNAL QUALITY
ASSESSMENT SCHEMES

Detection of TP53 gene mutations (Sanger Sequencing)

ORGANIZATION

Instand e.V

SCHEME

Molecular Oncology TP53

Detection of TP53 gene mutations by next-generation sequencing

ORGANIZATION

GenQA-ERIC

SCHEME

TP53 Certification

Determination of T cell receptor β chain gene rearrangements

ORGANIZATION

UK NEQAS

SCHEME

TCR Clonality Status

Determination of immunoglobulin heavy chain gene rearrangements

ORGANIZATION

UK NEQAS

SCHEME

IgH Clonality Status

Molecular detection of the SARS-CoV-2 virus

ORGANIZATION

EMQN_ QCMD Quality Control for Molecular Diagnostics

SCHEME

SARS-CoV-2 EQA Programme

Detection of mutations in hematologic malignancies

ORGANIZATION

EMQN_ QCMD Quality Control for Molecular Diagnostics

SCHEME

ONCOGENE_PANEL-22

Determination of IGHV gene somatic hypermutation status

ORGANIZATION

UK NEQAS

SCHEME

Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status_GenQA

Detection of mutations in solid tumors

ORGANIZATION

EMQN_ QCMD Quality Control for Molecular Diagnostics

SCHEME

ONCOGENE_PANEL-22

Detection of TP53 gene mutations by next-generation sequencing

ORGANIZATION

ERIC, European Research Initiative on CLL

SCHEME

TP53 Certification

Determination of IGHV gene somatic hypermutation status

ORGANIZATION

ERIC, European Research Initiative on CLL

SCHEME

Chronic Lymphocytic Leukemia (CLL) IGHV mutation status